Highest-materiality recent filing
Q1 2026 net revenues $5.1M vs $3.2M YoY; operating loss narrowed to $0.3M from $1.5M.
FOXO Technologies completes 1-for-3,000 reverse stock split effective June 30, 2026
Reverse split at 1:3,000 ratio; effective 4:01 p.m. ET on June 30, 2026.
FOXO licenses epigenetics IP to founder's entity; 3% royalty capped at $1.3M, 40% equity option
Exclusive worldwide license of two U.S. patents, 13,000+ dataset, and ML models to LongevityFP Technologies, controlled by founder Jon R. Sabes.
FOXO settles Darbie obligations; shareholder approves 1:1,000–1:10,000 reverse split
Issued 400 Series D Preferred shares to J.H. Darbie; pays $175,000 in 7 monthly installments to resolve all amounts owed.
Exchanged 2,467.988 shares of Series A Preferred ($2.47M stated value) from Investor 1 for a senior unsecured note.
FOXO Technologies increases authorized shares to 25.02B, effective May 3, 2026
Authorized shares raised to 25.02B: 25B Class A common ($0.0001 par) and 20M preferred ($0.0001 par).
FOXO Technologies majority stockholder approves authorized share increase from 10B to 25B
Majority stockholder (Rennova Health, Inc., controlled by CEO) holding 97.59% voting rights approved via written consent on March 27, 2026.
Sylwia Nowak Hauman resigned as CFO on March 18, 2026; resignation letter cited concerns over internal controls, financial reporting, and team resourcing.
FOXO settles $200K debt by issuing 8,000 Series E Preferred shares to Rennova in related-party deal
Issued 8,000 Series E Preferred shares at $25 stated value to Rennova in full satisfaction of $200,000 in Prior Advances.
FOXO Tech increases authorized common shares from 2.5B to 10B; hospital adds tele-specialty
Authorized shares of common stock increased to 10B from 2.5B, effective Jan 18, 2026.
Filed amendments to Series B and C Preferred Stock, revising conversion price to higher of $0.0001 or 90% of 5-day VWAP and removing mandatory conversion.
FOXO CEO year-end review: revenue >$15M expected, Myrtle occupancy 93%, debt reduced
Myrtle Recovery Centers avg daily census 28 (93% occupancy) vs 7.4 (25%) in 2024; projected 550 admissions vs 195.
FOXO subsidiary Myrtle Recovery Centers recognized by Tennessee rural health association
Myrtle Recovery Centers received recognition from Rural Health Association of Tennessee at annual awards luncheon on Dec 9, 2025.
FOXO Technologies amends Series D conversion price and Series E dividend frequency
Series D conversion price changed to the higher of $0.0001 or 90% of 5-day VWAP prior to conversion notice.
FOXO Technologies increases authorized common shares from 500M to 2.5B
Authorized common shares increased from 500,000,000 to 2,500,000,000 effective Oct 22, 2025.
FOXO appoints Sylwia Nowak Hauman as CFO, amends Series A Preferred terms
Sylwia Nowak Hauman appointed CFO (Principal Financial & Accounting Officer) effective September 23, 2025.
FOXO closes acquisition of Vector Bio Source; $500K cash, preferred stock, and warrants
On Sept 19, 2025, FOXO completed the purchase of Vector Bio Source, which became a wholly owned subsidiary.
Majority stockholder approves 5x increase in authorized Class A common shares to 2.5B
Majority stockholder (Rennova Health, controlled by CEO) holding 56.71% of voting rights approved share authorization increase.
FOXO Technologies signs agreement to acquire Vector Biosource Inc.
Purchase price: $500K cash, 60K Series E Preferred ($1.5M stated value), warrants for $2M common stock at 10% premium to closing price.
FOXO acquires Vector BioSource for $500K cash, Series E shares, and warrants
Purchase price includes $500K cash, 60,000 Series E Preferred shares, and warrants for up to $2M common stock at 110% of pre-close price.
Majority stockholder approves reverse stock split of FOXO common stock at ratio up to 1:500
Rennova Health (controlled by CEO) holds 60% voting rights, approved reverse split via written consent on Sept 2, 2025.
FOXO Technologies amends Smithline settlement, pays $97,837 in cash
Amendment No. 1 to Settlement Agreement dated Sept 4, 2025; remaining balance of $97,837 to be paid in cash.
FOXO delisted from NYSE American; board restates Q1 2025 financials for $5.1M error
NYSE American commenced delisting on Aug 12, 2025 due to stock price below $0.10; trading suspended immediately.
FOXO Technologies receives NYSE American delisting notice, moves to OTC market
NYSE Regulation commenced delisting proceedings on Aug 12, 2025 due to low selling price below $0.10.
Facility has 87 units licensed for assisted living and memory care services.
FOXO subsidiary Myrtle Recovery renews Oneida, TN license; facility at full capacity
License renewed by Tennessee DMHSAS after successful annual inspection for alcohol/drug residential treatment.
FOXO Technologies implements 1-for-1.99 reverse stock split effective July 27, 2025
Reverse stock split at 1:1.99 ratio; every 1.99 pre-split shares become 1 share, par value unchanged.
FOXO Tech board approves spin-off of epigenetics subsidiary FOXO Labs
Board approved pursuing spin-off of FOXO Labs, Inc., its epigenetics subsidiary; FOXO shareholders to directly own shares in the new entity.
FOXO Technologies approves 1-for-1.99 reverse stock split to meet NYSE American listing requirement
Reverse split ratio of 1:1.99; effective at 4:01pm ET on July 27, 2025.
FOXO subsidiary Myrtle Recovery approved for second year of Scott County opioid abatement funds
Myrtle Recovery Centers approved to receive Scott County Opioid Abatement Funds for a second year, starting July 1, 2025.
FOXO Technologies designates Series E Preferred Stock for acquisitions
Series E Preferred Stock: $25 stated value, 2.5% annual cash dividend paid semi-annually, plus 5.0% common stock dividend paid semi-annually.
FOXO Technologies majority stockholder approves 1:1.99 reverse split and multiple share issuances
Majority stockholder (82.08% voting rights) approved reverse stock split at 1:1.99 ratio, effective by Nov 6, 2025.
FOXO's Big South Fork Medical Center launches wound care services, aiming to boost revenues
Big South Fork Medical Center in Oneida, TN begins inpatient and outpatient wound care.
Formed FOXO Acquisition Corp., a wholly-owned subsidiary for healthcare services acquisitions; plans to create publicly listed non-convertible preferred stock for funding.
Issuance of up to 1,650 shares of Series A Cumulative Convertible Redeemable Preferred Stock at three closings of 550 shares each.
FOXO subsidiary Big South Fork Medical Center to launch wound care services on June 2, 2025
Big South Fork Medical Center in Oneida, TN will offer wound care services on inpatient and outpatient basis starting June 2, 2025.
FOXO subsidiary Myrtle Recovery hits 5,000 patient care days, targets 10,000 by year-end 2025
Over 400 patients served at Oneida, Tennessee facility since operations began August 2023.
FOXO Technologies completes 1-for-10 reverse stock split effective April 28
Effective 4:01pm ET April 28, 2025, every 10 pre-split shares consolidated into 1 post-split share.
FOXO Technologies announces 1-for-10 reverse stock split effective April 28, 2025
Reverse stock split ratio set at 1-for-10, effective at 4:01 p.m. ET on April 28, 2025.
FOXO files 10-K with going concern opinion; CEO cites transition year and acquisitions
Annual Report on Form 10-K filed on April 15, 2025 for fiscal year ended December 31, 2024.
FOXO Technologies announces 1-for-10 reverse stock split effective April 28, 2025
Reverse stock split at ratio 1:10, effective 4:01pm ET on April 28, 2025.
FOXO amends Series D Preferred Stock to remove automatic conversion, reclassifying shares as equity
Removes Section 6(e), the automatic conversion right at two-year anniversary from issuance.
FOXO signs non-binding deal to acquire Vector Biosource for up to $1.5M in preferred stock
Purchase price includes $750K Series D Preferred at close, plus $750K upon 2025 milestones.
Holder of 69.58% of Series D Preferred approved amendment to remove automatic conversion right at two-year anniversary.
FOXO subsidiary Myrtle Recovery reaches 75%+ occupancy, signs managed care contracts
Oneida, TN substance abuse facility maintained occupancy rate of 75%+ since start of 2025; occasionally at capacity.
Approved issuance to ClearThink Capital Partners for convertible note conversions and inducement shares.
FOXO executes non-binding agreement to acquire two Florida assisted living facilities for $60M
Total consideration $60M ($30M per facility), with a portion milestone-based.
FOXO CEO reports change of control, debt restructuring, and plans for revenue growth
Shareholders meeting Jan 17, 2025 concluded 2024 acquisition agreements, resulting in change of control of company.
Aggregate principal of $3,457,500 of 15% Senior PIK Notes cancelled and exchanged for 3,457.5 shares of Series B Preferred Stock.
FOXO shareholders approve issuance of common shares upon conversion of Series A Preferred Stock
Proposal 1 passed: 9,188,041 for, 103,224 against, 670,699 abstain; authorizes conversion-triggered share issuance above 20% of outstanding.
On June 9, 2025, Martin Ward, the Company’s Interim Chief Financial Officer passed away unexpectedly.
On June 13, 2025, the Board of Directors of the Company (with Mr. Lagan abstaining) appointed Seamus Lagan to serve as the Company’s Interim Chief Financial Officer.
the board of directors (the “ Board ”) of the Company appointed Seamus Lagan and Trevor Langley to the Board to serve as directors of the Company, effective September 10, 2024.
the board of directors (the “ Board ”) of the Company appointed Seamus Lagan and Trevor Langley to the Board to serve as directors of the Company, effective September 10, 2024.
appointed Francis Colt deWolf III to the Board to serve as a director of the Company, effective immediately.
Effective November 21, 2023, the Company accepted the resignation of Andrew Poole from the Board of Directors of the Company.
On September 13, 2023, Tyler Danielson notified the Company of his decision to resign as Interim Chief Executive Officer and Chief Technology Officer of the Company, effective as of September 14, 2023.
appointed Mark White to serve as Interim Chief Executive Officer of the Company, effective as of Mr. White’s entry into his employment agreement with the Company
On September 14, 2023, Brian Chen resigned as Chief Science Officer of the Company, pursuant to a resignation letter, effective immediately.
On September 14, 2023, the Company terminated the employment of Michael Will as General Counsel of the Company, effective as of such date, due to the Company’s current financial constraints and the need to reduce its staff.
the board of directors (the “Board”) of the Company (i) elected Mark White to the Board to serve as a director of the Company, effective immediately
Martin Ward to serve as Interim Chief Financial Officer of the Company, effective as of Mr. Ward’s entry into his employment agreement with the Company
Max materiality 0.85 · Median 0.57 · Most common event other_material